Clinical trials: multiple sclerosis
Relapsing Remitting Multiple Sclerosis
Treatment Interruption of Natalizumab
This is a randomized, rater blinded trial in patients who interrupt treatment with natalizumab with or without being treated with other immunomodulatory drugs, or continue treatment with natalizumab.
- Trial name
- RESTORE (NCT01071083)
- Testing
- natalizumab, interferon beta 1-a, methylprednisolone
- Where
- 33 sites in United States, Germany and 1 more
- Volunteers
- 175 people
- Sponsor
- Biogen
Multiple Sclerosis, Fatigue
Telephone-Delivered Exercise for Multiple Sclerosis Fatigue
Multiple sclerosis (MS) is a progressive demyelinating disorder that damages white matter in the central nervous system. Although individuals experience mobility (e.g., walking, balance) impairments that lower quality of life and…
- Conditions
- Multiple Sclerosis, Fatigue, Physical Activity
- Trial name
- NCT03256851
- Testing
- Telephone-Delivered Exercise Therapy, In-Person Delivered Exercise Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wayne State University
Multiple Sclerosis
Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)
This study will: Explore whether GA decreases inflammation more on the 3T optimized protocol when compared to the 1.5T standard protocol.
- Trial name
- NCT00937157
- Testing
- Copaxone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University at Buffalo
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
This study will evaluate if giving insulin that is administered in the nostrils (intranasal) is safe and tolerable for people with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
- Trial name
- NCT02988401
- Testing
- Insulin
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Johns Hopkins University
Neuropathic Pain, Chronic Pain
Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis
This study will determine whether treatment with an extended-release opioid or topical lidocaine is effective in relieving distal symmetric lower extremity burning pain associated with multiple sclerosis (MS).
- Conditions
- Neuropathic Pain, Chronic Pain, Multiple Sclerosis
- Trial name
- NCT00414453
- Testing
- Lidocaine patch 5%, Extended-release oxycodone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Rochester
Multiple Sclerosis
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e.
- Trial name
- NCT03599245
- Testing
- Ocrelizumab
- Where
- 161 sites in Argentina, Belgium and 24 more
- Volunteers
- 1,055 people
- Sponsor
- Hoffmann-La Roche
Nonmalignant Neoplasm, Tuberous Sclerosis
RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
This research study is evaluating a drug called rapamycin as a possible treatment for the lumps (or tumors) that form in the kidneys, called angiomyolipomas, in people who have either TSC or LAM.
- Conditions
- Nonmalignant Neoplasm, Tuberous Sclerosis, Lymphangioleimyomatosis, Kidney Angiomyolipoma
- Trial name
- NCT00126672
- Testing
- Rapamycin
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
Relapsing Remitting Multiple Sclerosis
Vitamin D Supplementation in Multiple Sclerosis
Low vitamin D levels have been shown to increase a person's risk of developing multiple sclerosis (MS), and patients with MS who have lower vitamin D levels are at increased risk of having attacks.
- Trial name
- NCT01490502
- Testing
- Vitamin D3
- Where
- 16 sites in United States
- Volunteers
- 172 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Back Pain
A Pilot Project for Multifidus Muscle Evaluation in Patients With Multiple Sclerosis
This research study plans to evaluate if multifidus muscle dysfunction is associated with back pain in patients with Multiple Sclerosis (MS).
- Trial name
- NCT05427045
- Testing
- home - exercise program
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Arkansas
Multiple Sclerosis
Methylphenidate to Improve Balance and Walking in MS
Methylphenidate is an amphetamine-like psychomotor stimulant drug currently approved for the treatment of attention-deficit hyperactivity disorder (ADHD), postural orthostasis tachycardia syndrome and narcolepsy.
- Trial name
- NCT01896700
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Oregon Health and Science University
Multiple Sclerosis
Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients
This study evaluates the effect of adding fish oil to Fingolimod on some serum cytokines in patients with Relapsing-Remitting Multiple Sclerosis.
- Trial name
- NCT02939079
- Testing
- Fingolimod, Fish Oil
- Volunteers
- 50 people
- Sponsor
- Isfahan University of Medical Sciences
Multiple Sclerosis
Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)
The primary objective of Part 1 of this study is to evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks.
- Trial name
- AFFINITY (NCT03222973)
- Testing
- BIIB033 (opicinumab)
- Where
- 159 sites in United States, Australia and 13 more
- Volunteers
- 263 people
- Sponsor
- Biogen
Multiple Sclerosis
Safety of Bryostatin in Patients With MS
This is a single-site, single-arm, single-dose, Phase 1 study of the safety of bryostatin in participants with multiple sclerosis (MS) receiving any disease modifying therapy (DMT).
- Trial name
- NCT06190912
- Testing
- Bryostatin 1
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Robert Fox
Multiple Sclerosis
Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS
The primary objective of this study is to determine if monthly pulse doses of a three-day course ACTH (H.P. Acthar®) is more effective at recovering myelin at 12 months, as measured by myelin water fraction (MWF), in new multiple…
- Trial name
- NCT02446886
- Testing
- Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Multiple Sclerosis
Duloxetine for Multiple Sclerosis Pain
This study is designed to primarily assess the efficacy and safety of duloxetine 60-120 mg once daily (QD) compared with placebo on the reduction of pain severity in participants with central neuropathic pain due to Multiple…
- Trial name
- NCT00755807
- Testing
- Duloxetine Hydrochloride (HCI)
- Where
- 22 sites in United States, Belgium and 2 more
- Volunteers
- 239 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
The primary objective of the study was to evaluate the immunogenicity of Avonex® (interferon beta-1a) 30 mcg when administered subcutaneously (SC) to interferon-naïve participants with relapsing multiple sclerosis.
- Trial name
- NCT00784836
- Testing
- BG9418 (interferon beta 1-a)
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Biogen
Multiple Sclerosis
Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY
The primary purpose of this single center, randomized, open label study in relapsing Multiple Sclerosis (MS) patients on PLEGRIDY (peginterferon beta-1a) is to assess the effect of Preparation H (phenylephrine) Maximum Strength…
- Trial name
- NCT02665221
- Testing
- No Treatment Arm, Topical Preparation H arm
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Spasticity, Multiple Sclerosis
A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
The purpose of this study is to determine whether Sativex® versus Placebo is effective in the relief of symptoms of spasticity in subjects with multiple sclerosis, who have been identified as having a capacity to respond to…
- Trial name
- NCT00681538
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 572 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis
Aspirin for Exercise in Multiple Sclerosis (ASPIRE)
This study investigates the use of aspirin as an exercise pre-treatment to reduce overheating and exhaustion, which may potentially allow many more people with multiple sclerosis to participate in and benefit from exercise.
- Trial name
- ASPIRE (NCT03824938)
- Testing
- Aspirin 650mg Oral Capsule, Acetaminophen Tablet 650mg
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Columbia University
Multiple Sclerosis
Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor
The purpose of this research study is to: 1. Determine whether deep brain stimulation (DBS) with two leads (very thin coiled wires) placed unilaterally (on one side of the brain) is beneficial to patients with multiple sclerosis…
- Trial name
- NCT00954421
- Testing
- Deep Brain Stimulation
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Florida